Ainos, Inc. (AIMD) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2025. Ainos, Inc. is an AI and healthcare company focused on scent digitization (AI Nose), point-of-care testing (POCT), and low-dose oral interferon therapeutics (VELDONA). The company operates as a single segment and is classified as a smaller reporting company. All share and per-share data have been retroactively adjusted for a 1-for-5 reverse stock split effective June 30, 2025.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $2,167 | $0 | $113,037 | $20,729 |
| Net Loss | $(2,931,702) | $(3,699,317) | $(10,302,714) | $(10,209,149) |
| Loss Per Share (Basic/Diluted) | $(0.64) | $(1.64) | $(2.61) | $(6.49) |
| Cash and Equivalents (End of Period) | $1,128,217 | $5,156,606 | $1,128,217 | $5,156,606 |
| Convertible Notes Payable | $11,000,000 | $12,000,000 | $11,000,000 | $12,000,000 |
| Accumulated Deficit | $(63,052,030) | $(48,095,304) | $(63,052,030) | $(48,095,304) |
Liquidity: Cash decreased by approximately $2.76 million during the nine months ended September 30, 2025. The company reported a net cash outflow from operating activities of $3.76 million for the nine-month period.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased from $0 in Q3 2024 to $2,167 in Q3 2025, driven by sales of VELDONA pet supplements and recognition of revenue from VOC sensing products related to NISD co-development.
- Expense Reduction: Operating expenses decreased by 8% in Q3 2025 compared to Q3 2024, primarily due to reduced share-based compensation and lower professional fees. However, SG&A expenses increased by 35% on a nine-month basis due to higher share-based compensation.
- Debt Repayment: The company repaid a $1,000,000 convertible note (Lee Note) in April 2025, reducing current liabilities.
- Stock Structure: A 1-for-5 reverse stock split was effectuated on June 30, 2025, to comply with Nasdaq listing rules. Outstanding shares are now approximately 4.79 million.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern for at least one year from the issuance date due to recurring losses and negative cash flows. Continued operations depend on securing additional financing.
- Capital Raising: The company utilized an At-the-Market (ATM) offering agreement, raising approximately $1.85 million in net proceeds during the first nine months of 2025. Subsequent sales in October and November 2025 raised an additional ~$68,000.
- Strategic Partnerships: Management highlighted a $2.1 million, three-year subscription order with ASE Technology Holding Co., Ltd. to deploy 1,400 AI Nose units. Partnerships with ugo, Inc. and Topco Scientific are advancing industrial and robotics applications.
- Risks: Key risks include the need for additional capital, foreign currency fluctuations (operations in Taiwan), and potential patent litigation. The company also faces risks related to the Trump Administration's trade policies and tariffs.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.13 million cash balance against the $3.76 million operating cash burn rate for the nine-month period.
- Debt Obligations: Confirm the terms and maturity dates of the $11 million in convertible notes payable, specifically the related-party ASE notes.
- Revenue Sustainability: Assess the scalability of the $2.1 million ASE order and the timing of revenue recognition for the AI Nose platform.
- Dilution Risk: Monitor the impact of the ATM offering and potential conversion of outstanding warrants (381,953 shares) and convertible notes on share count.
- Going Concern Status: Review the company's specific plans for raising capital to address the substantial doubt disclosed in the financial statements.